Table 3.

Multivariable linear regression of factors associated with 2-h glucose (mg/dL) in all HIV-infected and control participants

	HIV+ subjects (n = 491)			Control subjects (n = 187)
	Estimate	95% CI	P value	Estimate	95% CI	P value
Female vs. male	−3.8	(−13.7 to 6.2)	0.46	12.5	(−2.6 to 27.5)	0.10
African American vs. Caucasian	−2.4	(−9.9 to 5.1)	0.53	4.1	(−5.0 to 13.1)	0.37
Other vs. Caucasian	0.75	(−9.6 to 11.1)	0.89
Age (per decade)	9.0	(4.4–13.5)	0.0001	2.2	(−10.3 to 14.8)	0.72
Drinks
<1 vs. none	−2.0	(−10.6 to 6.6)	0.65	−1.8	(−17.2 to 13.6)	0.82
1–7 vs. none	−7.5	(−15.2 to 0.27)	0.059	−0.81	(−15.7 to 14.1)	0.92
>7 vs. none	−17.6	(−28.6 to −6.5)	0.0019	−0.10	(−19.8 to 19.6)	0.99
Physical activity
2nd vs. 1st quartile	8.4	(−1.11 to 17.8)	0.084	3.2	(−11.6 to 18.0)	0.67
3rd vs. 1st quartile	0.64	(−9.1 to 10.3)	0.90	9.6	(−3.3 to 22.5)	0.14
4th vs. 1st quartile	−10.5	(−18.4 to −2.7)	0.0088	5.4	(−8.4 to 19.3)	0.44
Upper trunk SAT (doubling)	13.8	(8.9–18.6)	<0.0001	20.4	(11.1–29.7)	<0.0001
Leg SAT (doubling)	−10.0	(−16.3 to −3.7)	0.0017	−16.4	(−30.4 to −2.5)	0.020
Tenofovir use	−7.4	(−14.1 to −0.59)	0.033
Pertinent negatives
VAT (doubling)	2.1	(−2.2 to 6.4)	0.34	5.8	(−4.4 to 15.9)	0.25
VAT-to-abdominal fat ratio (doubling)	3.4	(−2.0 to 8.8)	0.22	−5.5	(−26.1 to 15.1)	0.59
Current vs. never smoking	2.0	(−5.8 to 9.8)	0.61	−1.9	(−19.3 to 15.4)	0.83
Past vs. never smoking	−1.3	(−9.9 to 7.3)	0.77	−2.7	(−15.8 to 10.3)	0.68

P values in boldface denote statistical significance at P < 0.05. Unselected factors are in italics; values shown are those that would result if the factors were added back to the model individually. Those with fasting glucose ≥126 mg/dL or taking diabetes medication are excluded. Separate models were constructed for HIV-infected and control participants.